Affordable Access

CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.

Authors
Type
Published Article
Journal
Research communications in chemical pathology and pharmacology
Publication Date
Volume
52
Issue
3
Pages
285–294
Identifiers
PMID: 3755540
Source
Medline

Abstract

A new thromboxane synthetase inhibitor, CGS-12970, was evaluated for its ability to reduce the extension of myocardial infarct size in rats. CGS-12970 was given at either 4 or 8 mg/kg following acute coronary artery ligation. Both myocardial creatine kinase (CK) and amino-nitrogen loss from the left ventricular free wall (LVFW) were used as indices of ischemic damage at 48 hours. Rats given only the vehicle following coronary artery ligation lost 4.9 +/- 0.5 IU/mg protein (p less than 0.001) CK activity from the LVFW. This loss of CK activity was only slightly reduced by CGS-12970 at 4 mg/kg. However, at 8 mg/kg, the CK depletion from the LVFW was significantly reduced (p less than 0.05). This protective effect was confirmed by similar curtailment (p less than 0.05) of the loss of nitrogenous compounds from ischemic myocardium, at the high dose of CGS-12970. These findings represent a protective effect of CGS-12970 in reducing the extent of ischemic cardiac damage following experimental coronary artery ligation.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F